Skip to main content
Top
Published in: AIDS and Behavior 2/2017

01-02-2017 | Original Paper

Measurement of Vaginal Microbicide Adherence Using Visual Inspection as Compared to Ultra Violet Light Assessment of Returned Empty Gel Applicators

Authors: Michele Upfold, Anneke Grobler, Fatima Suleman, Leila E. Mansoor

Published in: AIDS and Behavior | Issue 2/2017

Login to get access

Abstract

Accurate and objective measurement of adherence is critical in microbicide trials. We compared two applicator tests: visual inspection of returned empty tenofovir gel applicators (VIREA) and ultraviolet light (UVL) assessment in terms of sensitivity and specificity, and for concordance. Sensitivity and specificity analysis of 24 control applicators (12 known-inserted and 12 sham-inserted) at 4-months after receipt was 75.0 and 66.7 % for VIREA and 83.3 and 91.7 % for UVL, respectively. After an additional 3 months of storage sensitivity and specificity was 100 and 58.3 % for VIREA and 100 and 66.7 % for UVL, respectively. In January 2015, 1316 empty applicators were returned as used by 115 participants enrolled at one site in a randomized controlled trial. Assessment outcomes showed 78.8 % agreement between the techniques. Methods concurred that 22.0 % of the returned empty applicators appeared unused. By UVL assessment, 40.0 % of returned empty applicators had no evidence of vaginal insertion, translating to a potential 28.0 % less product used as compared to that returned as used by women. UVL assessment may be considered a more accurate and less subjective measure of adherence as compared to VIREA.
Literature
2.
go back to reference Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168–74.CrossRefPubMedPubMedCentral Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329(5996):1168–74.CrossRefPubMedPubMedCentral
3.
go back to reference Spilker B. Methods of assessing and improving patient compliance in clinical trials. IRB: Eth Hum Res. 1992;14(3):1–6.CrossRef Spilker B. Methods of assessing and improving patient compliance in clinical trials. IRB: Eth Hum Res. 1992;14(3):1–6.CrossRef
5.
go back to reference Marrazzo JM, Ramjee G, Richardson BA, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372(6):509–18.CrossRefPubMedPubMedCentral Marrazzo JM, Ramjee G, Richardson BA, et al. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015;372(6):509–18.CrossRefPubMedPubMedCentral
6.
go back to reference van der Straten A, Montgomery ET, Hartmann M, Minnis A. Methodological lessons from clinical trials and the future of microbicide research. Curr HIV/AIDS Rep. 2013;10(1):89–102.CrossRefPubMed van der Straten A, Montgomery ET, Hartmann M, Minnis A. Methodological lessons from clinical trials and the future of microbicide research. Curr HIV/AIDS Rep. 2013;10(1):89–102.CrossRefPubMed
7.
go back to reference Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther. 1999;21(6):1074–90.CrossRefPubMed Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Ther. 1999;21(6):1074–90.CrossRefPubMed
8.
go back to reference Muchomba FM, Gearing RE, Simoni JM, El-Bassel N. State of the science of adherence in pre-exposure prophylaxis and microbicide trials. J Acquir Immune Defic Syndr. 2012;61(4):490–8.CrossRefPubMedPubMedCentral Muchomba FM, Gearing RE, Simoni JM, El-Bassel N. State of the science of adherence in pre-exposure prophylaxis and microbicide trials. J Acquir Immune Defic Syndr. 2012;61(4):490–8.CrossRefPubMedPubMedCentral
9.
go back to reference Tolley EE, Harrison PF, Goetghebeur E, et al. Adherence and its measurement in phase 2/3 microbicide trials. AIDS Behav. 2010;14(5):1124–36.CrossRefPubMed Tolley EE, Harrison PF, Goetghebeur E, et al. Adherence and its measurement in phase 2/3 microbicide trials. AIDS Behav. 2010;14(5):1124–36.CrossRefPubMed
10.
go back to reference Gengiah TN, Upfold M, Naidoo A, et al. Monitoring microbicide gel use with real-time notification of the container’s opening events: results of the CAPRISA Wisebag study. AIDS Behav. 2014;18(5):833–40.CrossRefPubMedPubMedCentral Gengiah TN, Upfold M, Naidoo A, et al. Monitoring microbicide gel use with real-time notification of the container’s opening events: results of the CAPRISA Wisebag study. AIDS Behav. 2014;18(5):833–40.CrossRefPubMedPubMedCentral
11.
go back to reference van der Straten A, Montgomery E, Pillay D, et al. Feasibility, performance, and acceptability of the Wisebag for potential monitoring of daily gel applicator use in Durban. South Africa AIDS Behav. 2013;17(2):640–8.CrossRefPubMed van der Straten A, Montgomery E, Pillay D, et al. Feasibility, performance, and acceptability of the Wisebag for potential monitoring of daily gel applicator use in Durban. South Africa AIDS Behav. 2013;17(2):640–8.CrossRefPubMed
12.
go back to reference Gengiah TN, Mansoor LE, Upfold M, et al. Measuring adherence by visual inspection of returned empty gel applicators in the CAPRISA 004 microbicide trial. AIDS Behav. 2014;18(5):820–5.CrossRefPubMedPubMedCentral Gengiah TN, Mansoor LE, Upfold M, et al. Measuring adherence by visual inspection of returned empty gel applicators in the CAPRISA 004 microbicide trial. AIDS Behav. 2014;18(5):820–5.CrossRefPubMedPubMedCentral
13.
go back to reference Austin MN, Rabe LK, Hillier SL. Limitations of the dye-based method for determining vaginal applicator use in microbicide trials. Sex Transm Dis. 2009;36(6):368–71.CrossRefPubMedPubMedCentral Austin MN, Rabe LK, Hillier SL. Limitations of the dye-based method for determining vaginal applicator use in microbicide trials. Sex Transm Dis. 2009;36(6):368–71.CrossRefPubMedPubMedCentral
14.
go back to reference van der Straten A, Cheng H, Mensch B, et al. Evaluation of 3 approaches for assessing adherence to vaginal gel application in clinical trials. Sex Transm Dis. 2013;40(12):950–6.CrossRefPubMedPubMedCentral van der Straten A, Cheng H, Mensch B, et al. Evaluation of 3 approaches for assessing adherence to vaginal gel application in clinical trials. Sex Transm Dis. 2013;40(12):950–6.CrossRefPubMedPubMedCentral
15.
go back to reference Keller MJ, Buckley N, Katzen LL, et al. Use of the dye stain assay and ultraviolet light test for assessing vaginal insertion of placebo-filled applicators before and after sex. Sex Transm Dis. 2013;40(12):939–43.CrossRefPubMedPubMedCentral Keller MJ, Buckley N, Katzen LL, et al. Use of the dye stain assay and ultraviolet light test for assessing vaginal insertion of placebo-filled applicators before and after sex. Sex Transm Dis. 2013;40(12):939–43.CrossRefPubMedPubMedCentral
16.
go back to reference Moench TR, O’Hanlon DE, Cone RA. Evaluation of microbicide gel adherence monitoring methods. Sex Transm Dis. 2012;39(5):335–40.CrossRefPubMed Moench TR, O’Hanlon DE, Cone RA. Evaluation of microbicide gel adherence monitoring methods. Sex Transm Dis. 2012;39(5):335–40.CrossRefPubMed
17.
go back to reference Thurman AR, Jacot TA, Kimble TD, et al. Comparison of visual and ultraviolet light inspection versus DNA/protein biomarkers to assess product adherence with vaginal microbicide applicators. Sex Transm Dis. 2014;41(12):739–46.CrossRefPubMed Thurman AR, Jacot TA, Kimble TD, et al. Comparison of visual and ultraviolet light inspection versus DNA/protein biomarkers to assess product adherence with vaginal microbicide applicators. Sex Transm Dis. 2014;41(12):739–46.CrossRefPubMed
18.
go back to reference Mansoor LE, Abdool Karim Q, Mngadi KT, et al. Assessing the implementation effectiveness and safety of 1% tenofovir gel provision through family planning services in KwaZulu-Natal, South Africa: study protocol for an open-label randomized controlled trial. Trials. 2014;15:496.CrossRefPubMedPubMedCentral Mansoor LE, Abdool Karim Q, Mngadi KT, et al. Assessing the implementation effectiveness and safety of 1% tenofovir gel provision through family planning services in KwaZulu-Natal, South Africa: study protocol for an open-label randomized controlled trial. Trials. 2014;15:496.CrossRefPubMedPubMedCentral
Metadata
Title
Measurement of Vaginal Microbicide Adherence Using Visual Inspection as Compared to Ultra Violet Light Assessment of Returned Empty Gel Applicators
Authors
Michele Upfold
Anneke Grobler
Fatima Suleman
Leila E. Mansoor
Publication date
01-02-2017
Publisher
Springer US
Published in
AIDS and Behavior / Issue 2/2017
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-016-1465-z

Other articles of this Issue 2/2017

AIDS and Behavior 2/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.